25792 Improvements in BSA associate with improvements in itch and quality of life in patients with moderate-to-severe psoriasis treated with ixekizumab or guselkumab through 24 weeks
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要